“We remain confident”

CooperCompanies announced financial results for its first fiscal quarter ended January 31, 2025. In the quarter, CooperCompanies reported that revenue increased 4 percent year over year to $964.7 million; CooperVision (CVI) revenue was up 4 percent to $646.1 million, and CooperSurgical (CSI) revenue was up 3 percent to $318.6 million. CooperCompanies currently has GAAP diluted earnings per share, up $0.11 from last year’s first quarter. Non-GAAP diluted EPS are $0.92, up $0.07 compared with last year’s first quarter.

Al White, Cooper’s president and CEO said, “We started the year on a positive note meeting our revenue expectations and exceeding our operational targets. Moving forward, we remain confident in our ability to deliver strong growth and operational excellence, and this is reflected in our guidance.”

First quarter 2025 operating results for CooperCompanies report a revenue of $964.7 million, up 4 percent compared with last year’s first quarter (up 5 percent in constant currency, up 5 percent organically), as well as a gross margin of 68 percent, compared with 67 percent in last year’s first quarter. CooperCompanies said this is driven by efficiency gains and mix. On a non-GAAP basis, gross margin was 69 percent, compared with 67 percent last year.

In the first quarter CooperCompanies had an operating margin of 19 percent, compared with 16 percent in last year’s first quarter. This was driven by strong gross margins and targeted G&A expenses leverage, CooperCompanies said. On a non-GAAP basis, operating margin was 25 percent, up from 24 percent last year.

CooperCompanies had an interest expense of $26.0 million in the first quarter, compared with $29.9 million in last year’s first quarter, which the company said was driven by lower interest rates and lower average debt. On a non-GAAP basis, interest expense was $25.3 million, down from $28.6 million in last year’s first quarter.

CooperCompanies reported cash provided by operations of $190.6 million offset by capital expenditures of $89.4 million, resulting in free cash flow of $101.2 million.

For CooperVision (CVI), in the first quarter of 2025, revenue was $646.1 million, up 4 percent compared with last year’s first quarter, up 6 percent in constant currency and up 6 percent organically.

For CooperSurgical (CSI), in the first quarter of 2025, revenue was  $318.6 million, up 3 percent compared with last year’s first quarter, up 4 percent in constant currency and up 2 percent organically.

Following these results, CooperCompanies has updated its fiscal year 2025 guidance. This guidance is now a fiscal 2025 total revenue of $4,080 million to $4,158 million (organic growth of 6 percent to 8 percent); within this, CVI revenue of $2,733 million to $2,786 million (organic growth of 6.5 percent to 8.5 percent); and CSI revenue of $1,347 million to $1,372 million (organic growth of 4 percent to 6 percent). Finally, fiscal 2025 non-GAAP diluted EPS of $3.94 to $4.02 (raised from previous guidance of $3.92 to $4.02.

CooperCompanies said non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses, including acquisition and integration costs which may incur as part of continuing operations. In addition, the company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measure. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the company said it is not able to provide such guidance.

A full report of CooperCompanies’ first quarter 2025 results is available on the company’s website.